Literature DB >> 17333164

Free energies of binding of R- and S-propranolol to wild-type and F483A mutant cytochrome P450 2D6 from molecular dynamics simulations.

Chris de Graaf1, Chris Oostenbrink, Peter H J Keizers, Barbara M A van Vugt-Lussenburg, Jan N M Commandeur, Nico P E Vermeulen.   

Abstract

Detailed molecular dynamics (MD) simulations have been performed to reproduce and rationalize the experimental finding that the F483A mutant of CYP2D6 has lower affinity for R-propranolol than for S-propranolol. Wild-type (WT) CYP2D6 does not show this stereospecificity. Four different approaches to calculate the free energy differences have been investigated and were compared to the experimental binding data. From the differences between calculations based on forward and backward processes and the closure of thermodynamic cycles, it was clear that not all simulations converged sufficiently. The approach that calculates the free energies of exchanging R-propranolol with S-propranolol in the F483A mutant relative to the exchange free energy in WT CYP2D6 accurately reproduced the experimental binding data. Careful inspection of the end-points of the MD simulations involved in this approach, allowed for a molecular interpretation of the observed differences.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17333164      PMCID: PMC1914272          DOI: 10.1007/s00249-006-0126-y

Source DB:  PubMed          Journal:  Eur Biophys J        ISSN: 0175-7571            Impact factor:   1.733


  35 in total

1.  A virtual high throughput screen for high affinity cytochrome P450cam substrates. Implications for in silico prediction of drug metabolism.

Authors:  G M Keseru
Journal:  J Comput Aided Mol Des       Date:  2001-07       Impact factor: 3.686

2.  The GROMOS software for biomolecular simulation: GROMOS05.

Authors:  Markus Christen; Philippe H Hünenberger; Dirk Bakowies; Riccardo Baron; Roland Bürgi; Daan P Geerke; Tim N Heinz; Mika A Kastenholz; Vincent Kräutler; Chris Oostenbrink; Christine Peter; Daniel Trzesniak; Wilfred F van Gunsteren
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

3.  The substrate specificity of cytochrome P450cam.

Authors:  Z Zhang; O Sibbesen; R A Johnson; P R Ortiz de Montellano
Journal:  Bioorg Med Chem       Date:  1998-09       Impact factor: 3.641

4.  Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy.

Authors:  C R Jefcoate
Journal:  Methods Enzymol       Date:  1978       Impact factor: 1.600

5.  A new method for predicting binding affinity in computer-aided drug design.

Authors:  J Aqvist; C Medina; J E Samuelsson
Journal:  Protein Eng       Date:  1994-03

6.  Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6.

Authors:  Chris de Graaf; Chris Oostenbrink; Peter H J Keizers; Barbara M A van Vugt-Lussenburg; Robert A B van Waterschoot; Richard A Tschirret-Guth; Jan N M Commandeur; Nico P E Vermeulen
Journal:  Curr Drug Metab       Date:  2007-01       Impact factor: 3.731

7.  Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.

Authors:  Peter H J Keizers; Barbara M A Lussenburg; Chris de Graaf; Letty M Mentink; Nico P E Vermeulen; Jan N M Commandeur
Journal:  Biochem Pharmacol       Date:  2004-12-01       Impact factor: 5.858

8.  Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking.

Authors:  Chris de Graaf; Chris Oostenbrink; Peter H J Keizers; Tushar van der Wijst; Aldo Jongejan; Nico P E Vermeulen
Journal:  J Med Chem       Date:  2006-04-20       Impact factor: 7.446

Review 9.  Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms.

Authors:  Magnus Ingelman-Sundberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-22       Impact factor: 3.000

10.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity.

Authors:  P A Williams; J Cosme; V Sridhar; E F Johnson; D E McRee
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

View more
  6 in total

1.  Molecular dynamics studies of modular polyketide synthase ketoreductase stereospecificity.

Authors:  Mauro L Mugnai; Yue Shi; Adrian T Keatinge-Clay; Ron Elber
Journal:  Biochemistry       Date:  2015-04-02       Impact factor: 3.162

2.  Towards automated binding affinity prediction using an iterative linear interaction energy approach.

Authors:  C Ruben Vosmeer; René Pool; Mariël F Van Stee; Lovorka Peric-Hassler; Nico P E Vermeulen; Daan P Geerke
Journal:  Int J Mol Sci       Date:  2014-01-09       Impact factor: 5.923

3.  Assessing the stability of free-energy perturbation calculations by performing variations in the method.

Authors:  Francesco Manzoni; Ulf Ryde
Journal:  J Comput Aided Mol Des       Date:  2018-03-13       Impact factor: 3.686

Review 4.  "Commandeuring" Xenobiotic Metabolism: Advances in Understanding Xenobiotic Metabolism.

Authors:  Barbara M A van Vugt-Lussenburg; Liliana Capinha; Jelle Reinen; Martijn Rooseboom; Michel Kranendonk; Rob C A Onderwater; Paul Jennings
Journal:  Chem Res Toxicol       Date:  2022-06-29       Impact factor: 3.973

5.  Rationalization of stereospecific binding of propranolol to cytochrome P450 2D6 by free energy calculations.

Authors:  Gabor Nagy; Chris Oostenbrink
Journal:  Eur Biophys J       Date:  2012-10-20       Impact factor: 1.733

6.  Entropic and enthalpic contributions to stereospecific ligand binding from enhanced sampling methods.

Authors:  Balder Lai; Gabor Nagy; Jose Antonio Garate; Chris Oostenbrink
Journal:  J Chem Inf Model       Date:  2014-01-09       Impact factor: 4.956

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.